Early diagnosis of lung cancer by detection of tumor liberated protein
- PMID: 15389637
- DOI: 10.1002/jcp.20195
Early diagnosis of lung cancer by detection of tumor liberated protein
Abstract
Tumor liberated protein (TLP) is a protein that can be used to reveal the early development of a tumor. Besides being formed in the tumor, TLP is released in the blood when a patient starts producing cancer cells, which in turn enables the physician to intervene at a stage when the cancer is operable. To date, the available studies of tumor markers in lung cancer patients are CEA, NSE, TPA, Chromogranine, CA125, CA19-9, and Cyfra 21-1. The sensitivity and specificity for serum markers ranges between 50 and 90%, depending on the study and the clinical samples analyzed. Most of these markers show an increased rate of positivity as the stage advances. There are very limited data on TLP to draw any firm conclusion regarding the diagnostic value of this marker. TLP has been detected in 53.1% of non-small cell lung cancer (NSCLC) patients (N = 534) with 75% being positive in the early stage (stage I) and dropping to 45% in the late stage (stage IV). However, 7.6% blood donor sera and 17.4% chronic lung disease sera have also tested positive. In a confirmation study, the specificity was 89.94% and the sensibility was 63.63% from stage III to IV NSCLC patients. In an initial study of TLP as a marker for early detection in stage I, NSCLC patients showed a sensitivity of 66.7% and a specificity of 80% for TLP compared to a sensitivity of 33.3% for CA19-9, 11.1% for Cyfra 21-1 and CA125, and 0% for CEA; the specificity for all four of the latter markers was 100%. Using immunohistochemical analysis with peroxidase anti-peroxidase (PAP), we observed that NSCLC cells were positive; we used the specific rabbit antiserum to TLP, which turned out negative in the presence of 1 mg/ml of the synthetized peptide. The pre-serum was also negative. The same reactivity was found early in the modified epithelial cells of interstitial lung fibrosis and might be a predictive marker of cell transformation. The site of the peroxidase positivity was cytoplasmic, of diffuse and/or granular type.
2004 Wiley-Liss, Inc.
Similar articles
-
A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP)--a possible new tumor marker.Anticancer Res. 1996 Jul-Aug;16(4B):2253-5. Anticancer Res. 1996. PMID: 8694552
-
Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res. 2003 Mar-Apr;23(2A):899-906. Anticancer Res. 2003. PMID: 12820320
-
Detection of lung cancer in silicosis patients using a tumor-marker panel.Cancer Biomark. 2010;6(3-4):137-48. doi: 10.3233/CBM-2009-0125. Cancer Biomark. 2010. PMID: 20660960
-
Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels.Cancer Biomark. 2010;6(3-4):149-62. doi: 10.3233/CBM-2009-0126. Cancer Biomark. 2010. PMID: 20660961 Review.
-
[Lung cancer].Gan To Kagaku Ryoho. 2004 Oct;31(10):1609-13. Gan To Kagaku Ryoho. 2004. PMID: 15508459 Review. Japanese.
Cited by
-
Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology.Lung. 2008 Jul-Aug;186(4):255-261. doi: 10.1007/s00408-008-9093-7. Epub 2008 May 9. Lung. 2008. PMID: 18465169
-
Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.Br J Cancer. 2016 Mar 1;114(5):532-44. doi: 10.1038/bjc.2015.348. Epub 2016 Feb 23. Br J Cancer. 2016. PMID: 26908325 Free PMC article.
-
The diagnostic efficacy of seven autoantibodies in early detection of ground-glass nodular lung adenocarcinoma.Front Oncol. 2024 Nov 26;14:1499140. doi: 10.3389/fonc.2024.1499140. eCollection 2024. Front Oncol. 2024. PMID: 39659784 Free PMC article.
-
Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC).J Clin Lab Anal. 2012 May;26(3):148-54. doi: 10.1002/jcla.21502. J Clin Lab Anal. 2012. PMID: 22628229 Free PMC article.
-
Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.Cancer Biol Ther. 2013 Dec;14(12):1104-12. doi: 10.4161/cbt.26370. Epub 2013 Sep 4. Cancer Biol Ther. 2013. PMID: 24025412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous